source
- Roche licenses Rona's ALK7 obesity candidate in $1.2 billion dealRoche has agreed to license an RNAi drug candidate targeting ALK7 from Chinese biotech Rona Therapeutics, with an upfront payment of $100 million and potential milestones up to $1.06 billion. The…
- Saudi Arabia signs 46 biotech agreements at Riyadh summit, targeting $1.5 bn investmentThe fourth Riyadh Global Medical Biotechnology Summit wrapped up on September 16, with 46 agreements signed among local and international participants. The disclosed agreements represent about 5.5…